Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14136603 | 0.83 | USP2 (0.45) | WDR5PTPN11 | |
| SCHEMBL14124976 | 0.83 | MEN1 (0.50) | AKR1C3CYP2C19HTTMEP1BRAB9A | |
| SCHEMBL14136527 | 0.78 | PPARD (0.43) | CYP2C19PTPN11 | |
| SCHEMBL16748752 | 0.77 | TP53 (0.34) | CYP2C19HTTRAB9A | |
| SCHEMBL14136604 | 0.76 | USP2 (0.45) | CYP2C19 | |
| SCHEMBL15279057 | 0.74 | TP53 (0.33) | WDR5S1PR3HTTPTPN11 | |
| SCHEMBL16748757 | 0.73 | S1PR2 (0.33) | S1PR3HTTS1PR1RAB9A | |
| SCHEMBL9915493 | 0.72 | SMN1; SMN2 (0.43) | CYP2C19RAB9A | |
| SCHEMBL9915355 | 0.71 | COMT (0.38) | CYP2C19RAB9A | |
| SCHEMBL9915436 | 0.71 | FAAH (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | WDR5 1512/4885AKR1C3 1792/4885CYP2C19 714/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | WDR5 1512/4885AKR1C3 1792/4885CYP2C19 714/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | WDR5 1512/4885AKR1C3 1792/4885CYP2C19 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.